49 results about "Chronic viral hepatitis B" patented technology

The invention provides detoxification strengthening powder for treating chronic viral hepatitis B, which comprises the following components in parts by weight: 15-25 parts of vinegar radix bupleuri, 15-25 parts of honey-fried licorice root, 60-75 parts of poria cocos, 60-75 parts of rhizoma atractylodis macrocephalae, 60-75 parts of radix paeoniae alba, 30-50 parts of angelica sinensis, 85-100 parts of honeysuckle flower, 80-100 parts of sculellaria barbata, 60-75 parts of raw astragalus membranaceus, 90-100 parts of the root of red-rooted salvia, 80-100 parts of raw barley, 30-45 parts of schisandra chinensis, 35-50 parts of the root bark of the peony tree, 35-50 parts of medlar and 30-50 parts of glossy privet fruit. By adopting multi-directional, multi-target and multi-link comprehensive treatment according to multiple complex mechanisms of diseases, the composition provided by the invention has the functions of balancing yin and yang and regulating the qi and blood of the chronic hepatitis B patients, so that the chronic hepatitis B patients have full healthy atmosphere, and the pathogenic factors can be removed. Each single medicine is not powerful; the components have different effects, for example, the honeysuckle flower can clear away heat and toxic materials but cannot replace angelica sinensis to nourish and regulate blood, and even more, the honeysuckle flower does not have the effect of medlar for nourishing liver and kidney. Each medicine should be reasonably combined with other medicines, so that both symptoms and root causes can be resolved, and a more remarkable clinical treatment effect can be obtained.

The invention relates to a medicinal composition for treating chronic hepatitis B, liver cirrhosis and liver fibrosis, which is mainly prepared from Chinese medicaments such as raidx astragali, pseudo-ginseng, fried turtle shell and fiveleaf gynostemma herb, can be prepared into conventional medicinal preparation, and is used for treating the chronic hepatitis B, the liver fibrosis, the liver cirrhosis and chemical liver injury.

The invention discloses a Chinese patent medicament for treating acute and chronic viral hepatitis type B, and relates to a Chinese medicament composition, in particular to a Chinese patent medicament for treating the acute and chronic viral hepatitis type B and ascites due to cirrhosis. The Chinese patent medicament is a Chinese medicinal formulation which is prepared from the following Chinese herbal medicine raw materials in portion by weight: 20 to 30 portions of Artemisia capillaris, 15 to 30 portions of cairo morningglory root, 25 to 30 portions of Zornia diphylla, 20 to 25 portions of Astragalus membranaceus, 15 to 20 portions of Paeonia lactiflora, 10 to 12 portions of bupleurum, 6 to 8 portions of liquorice, 0 to 15 portions of swertia, 8 to 10 portions of cape jasmine, 20 to 25 portions of stringy stonecrop and 20 to 25 portions of European verbena. The formulation can be powders, pills, tablets, medicinal granules, capsules and oral liquid.

The Chinese medicine for treating chronic viral hepatitis B is prepared with capillary artemisia, herba patriniae, gentian root, cogongrass rhizome, white peony root and other 18 kinds of Chinese medicinal materials in certain weight proportion and through special processing. The synergistic effects of the medicine materials make the Chinese medicine possess functions of clearing away heat, promoting diuresis, treating jaundice, soothing the liver and invigorating spleen. The Chinese medicine has high clinical curative effect.

An injection containing methylcantharidimide for treating primary liver cancer and chronic viral hepatitis B is prepared through dissolving methylcantharidimide in solvent, decarbonizing, filtering, freeze drying and sterilizing.

The invention discloses a Chinese herbal preparation used for treating chronic viral hepatitis type b, comprising the following raw materials in percentage by weight: 4.5-10% of herba patriniae, 4.5-10% of coix seed, 4.5-5% of ginseng, 4.5-5% of white atractylodes rhizome, 4.5-5% of roasted milk vetch, 4.5-5% of eucommia bark, 9-10% of semen cuscutae, 1-2% of coptis chinensis, 2-3% of prepared pinellia ternate, 2-3% of dried tangerine or orange peel, 5-6% of white paeony root, 9-10% of prepared rehmannia root, 2.8-3.1% of salviae miltiorrhizae, 2.8-3.1% of safflower, 2.8-3.1% of peach kernel, 4-5% of liquorice, 2.8-3.1% of green tangerine peel, 6-6.5% of bupleurum, 4.5-5% of fingered citron, 9-10% of prepared turtle shell, 3-3.7% of poria cocos and 1.6-1.9% of rhizoma alismatis. The invention also provides a taking method of the Chinese herbal preparation. The Chinese herbal preparation disclosed by the invention has the advantages of good curative effect and no side effect, and the chronic viral hepatitis type b and a hepatitis B virus carrier can be fundamentally treated.

The invention discloses a liver treating drink for treating acute and chronic viral hepatitis B, which is prepared from the following Chinese herbal medicines: kummerowia striata, red sage root, oldenlandia diffusa, phyllanthus urinaria, fried bighead atractylodes rhizome, stringy stonecrop, cogongrass rhizome, gizzard pepsin, self-heal, boneset and oriental wormwood. The invention also relates to a preparation method of the drink and an application of the drink for treating viral hepatitis B. The clinical test shows that the drink has the functions of eliminating hepatitis B virus, regulating immunity, protecting the liver, reducing enzyme and the like, and has obvious effects on treating acute icteric hepatitis, anicteric hepatitis and chronic viral hepatitis B.

The present invention relates to kurarinol dispersing tablet, and belongs to the field of medicine technology. The kurarinol dispersing tablet consists of kurarinol 1-65 wt%, disintegrating agent 2-90 wt%, lubricant and flow assistant 0-20 wt% and adhesive 0-20 wt%. The preparation process of the kurarinol dispersing tablet includes sieving the said components, mixing kurarinol and disintegrating agent, adding adhesive to form soft material, pelletizing, stoving, finishing, mixing with disintegrating agent, lubricant and flow assistant, measuring the content of kurarinol in pellet, weighing, and tablet pressing to obtain kurarinol dispersing tablet. The medicine may be taken after being dispersed in water, chewed or swallowed, and is used clinically in treating chronic viral hepatitis B, leucopenia caused by different reasons and allergic dermatosis. The medicine has the advantages of good dispersing state, high bioavailability, etc.

A Chinese medicine in the form of particles for treating chronic hepatitis B is prepared from 12 Chinese-medicinal materials including pseudostellaria root, wolfberry fruit, red peony root, liquorice root, etc through proportionally pretreating, concentrating, drying, pulverizing and granulating. Its advantage is high curative effect (93.66%).

The invention discloses a Chinese medicinal injection for treating jaundice and a preparation method thereof, which belong to the technical field of Chinese medicinal preparations. The preparation method of the Chinese medicinal injection comprises the following steps of: performing water cooking and alcohol deposition on virgate wormwood herb, fructus gardenia, baikal skullcap root and coptis root to obtain an acid alcohol liquid, performing ethanol percolation on amur corktree bark and rhubarb to obtain an ethanol percolate, mixing the acid alcohol liquid with the ethanol percolate, performing alcohol deposition, adding a concentrated ammonium solution for adjusting the pH value to 8.0-9.0, extracting a supernatant to obtain an alkaline alcohol liquid, concentrating under reduced pressure, and recovering ethanol to obtain a liquid medicament; and adding a proper amount of water for injection into the liquid medicament, filtering and sterilizing to obtain a Chinese medicinal injection for treating jaundice, wherein every 1mL of Chinese medicine injection contains more than or equal to 1.0mg of geniposide C17H24011. The Chinese medicinal injection provided by the invention has the advantage of good treatment effect on jaundice of chronic virus B hepatitis.

The present invention discloses a non-creative scoring model for ULN chronic hepatitis B and hepatic fibrosis and establishment method therefor. According to the non-creative scoring model for the ULN CHB and hepatic fibrosis, 249 chronic virus hepatitis B patients whose ALT is lower than twice of ULT are selected, clinical conventional indicators are screened, relevance between each indicator and hepatic fibrosis is analyzed one by one at a Spearman level, six indicators are selected from the indicators whose P is lower than 0.05, and r is greater than 0.259, and a scoring model DMFibroS is established; scores are obtained and accumulated by computing a relative ratio of each indicator, and diagnostic ability is evaluated and verified by using a working characteristic curve of subjects; area fluctuation under the working characteristic curve is determined to be from 0.660 to 0.777 upon diagnosis by analyzing subjects subjected to hepatic fibrosis based on the six indicators; and the DMFibroS model is established in combination of the six indicators. The method according to the present invention is simple, and the operation is convenient, which makes up for the margin of the industry.

The medicine for treating chronic hepatitis is prepared with capillary artemisia, white peony root, prepared fleeceflower root, wolfberry fruit, schisandra and prepared licorice in certain weight proportion. The medicine treats chronic viral hepatitis B through nourishing Yin and softening liver, and has high curative effect and little side effects. The present invention also discloses the preparation process of the medicine.

The invention provides a traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B related decompensated hepatic cirrhosis. The traditional Chinese medicine compositionat least comprises the following medicinal raw materials: astragalus membranaceus, oriental wormwood, scutellaria baicalensis, coptis chinensis, golden cypress, curcuma zedoary, processed turtle shell, scorched hawthorn fruit, radix paeoniae alba, campsis grandiflora, bran-fried atractylodes macrocephala koidz, poria cocos, radix bupleuri and oldenlandia diffusa. The traditional Chinese medicinecomposition has the advantages as follows: on the basis of realizing the treatment of chronic hepatitis B and liver cirrhosis, the development evolution of chronic hepatitis B-liver cirrhosis-liver cancer is cut off, the vacancy that chronic viral hepatitis B and hepatic cirrhosis cannot be simultaneously treated at present is made up, the occurrence of hepatic cirrhosis and liver cancer is reduced, the annual incidence rate of hepatic cirrhosis of a chronic hepatitis B patient is reduced to 1% from 2-10%, and the annual incidence rate of primary liver cancer of a hepatitis B related decompensated hepatic cirrhosis patient is reduced to 1% from 3%-6%, so that the lifetime of the patient is prolonged, the burden of the patient is reduced, and medical expenditure is saved for the country. Inaddition, the invention also provides other nine traditional Chinese medicine compositions obtained by the basic formula.

The invention belongs to the technical field of biomedicine, relates to a hepatitis B virus (HBV) vaccine and a preparation method thereof and further relates to application of the vaccine in prevention of hepatitis B virus infection and treatment of chronic hepatitis B (CHB) infection and application of the vaccine in cooperation with an HBsAg vaccine in treatment of CHB. The vaccine comprises a hepatitis B virus envelope protein preS1 region, can effectively prevent HBV from infecting a host, has a treatment effect on chronic hepatitis virus infection, and achieves a more remarkable effect than that of a traditional HBV vaccine in the prior art.

The invention belongs to the technical field of medicine controlled release preparations, particularly discloses kurarinone osmotic pump controlled release tablets, and further discloses a preparation method of the kurarinone osmotic pump controlled release tablets. The kurarinone osmotic pump controlled release tablets are prepared from kurarinone tablets and protective films outside the tablets, wherein the tablets are prepared from core tablets and semipermeable films outside the core tablets; a medicine release hole is formed in each semipermeable film; the core tablets are prepared from the following raw materials in percentage by weight: 40.00%-60.00% of kurarinone, 15.00%-25.00% of sodium chloride, 20.00%-30.00% of lactose, 2.00%-5.00% of hydroxypropyl methylcellulose, 1.00%-3.50% of polyvinylpyrrolidone and 0.50%-2.00% of magnesium stearate. The kurarinone osmotic pump controlled release tablets provided by the invention can keep favorable zero-order medicine release within 20 hours, the final total release amount exceeds 70%, and part of the final total release amount exceeds 80%, so that the kurarinone osmotic pump controlled release tablets can be clinically used for treating Chronic Hepatitis B.

The invention discloses a longevity plasma cell capable of secreting a PD-1 antibody as well as a preparation method and application of the longevity plasma cell. The method specifically comprises thefollowing steps: integrating a PD-1 antibody gene into a B cell at a fixed point to obtain a genetically engineered B cell; and inducing the genetically engineered B cell into a longevity plasma cellsecreting a PD-1 antibody. The prepared longevity plasma cell capable of secreting the PD-1 antibody has typical phenotype and transcription characteristics of the longevity plasma cell; in addition,a large number of PD-1 antibodies can be continuously secreted, PD-1 antibody drug-mediated tumor immunotherapy is expected to be replaced, Meanwhile, a new thought is provided for tumor adoptive cellular immunotherapy. Moreover, the antibody gene is introduced into B cells to be induced into long-life plasma cells capable of continuously secreting a large number of antibodies; the new thought therapy for treating the long-life plasma cell transfused patient not only can be used for treating various tumors, but also has a wide application prospect in various infectious diseases such as AIDS (acquired immune deficiency syndrome) and chronic viral hepatitis B, and protein-deficient diseases such as hemophilia.

The invention belongs to the technical field of traditional Chinese medicine, and aims to provide a decoction medicine for treating chronic viral hepatitis B according to the understanding mechanism of chronic viral hepatitis B in traditional Chinese medicine. The components of the medicine and their mass ratios are as follows : Astragalus 15-32g, Salvia miltiorrhiza 5-20g, white back leaf 25-45g, Ligustrum lucidum 8-16g, medlar 10-22g, Smilax 15-55g, Bupleurum 3-12g, Poria 15-26g, Schisandra 3 ~6g, Codonopsis 15~26g, pinellia (made) 3~9g, yam 15~32g, Radix Radix 30~48g, Atractylodes macrocephala 8~16g, turmeric 8~16g, white peony root (wine fried) 10~22g, white snake Tongica 15-30g, Angelica 8-16g, Chenpi 6-10g, Honeysuckle 15-26g, Polygonatum 15-25g, Polygonum cuspidatum 15-30g, Jiaohawthorn 3-10g; the medicine provided by the invention is a good traditional Chinese medicine prescription .

The invention is a compound recipe Liuyueqing capsule (LYQC) composed of 15g of plug malan, 15g of oldenlandia diffusa, 15g of cape jasmine root, 15g of herba scutellariae barbatae, 15g of lawn pennywort herb and 15g of stringy stonecrop, which aims to provide a new effective Chinese herbal medicine composition for treating hepatitis B and solve the problem of bad hepatitis B therapeutic effect. Long term and plentiful investigations find that the LYQC can effectively protect the acute liver injuries in mice induced by carbon tetrachloride, Acetaminophen and D-Galactosamine; and can obviously restrict HBsAg and HBeAg in serum in vitro and HBV in vivo and in vitro with rather low toxicity. The investigations show that the invention can provide new medicament with good curative effect for acute viral hepatitis B and CVH chronic viral hepatitis B, hepatic fibrosis and hepatitis B virus carriers.

The invention discloses a traditional Chinese medicine composition for treating chronic type viral hepatitis B, which belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following two sets of medicines, wherein the crude medicines in the first set include sedum sarmentosum bunge, rubia cordifolia, morinda officinalis, angelica sinensis, radix paeoniae rubra, codonopsis pilosula, resina draconis, Chinese date, radix isatidis, radix puerariae, herba artemisiae scopariae, cimicifuga foetida, schisandra chinensis, fructus lycii, radix sophorae tonkinensis, rhubarb, panax notoginseng and radix bupleuri; and the crude medicines in the second set include salvia miltiorrhiza, carapax trionycis, rhizoma phragmitis, herba leonuri, aspongopus chinensis dallas, fructus ligustri lucidi, endothelium corneum, rhizoma curcumae and radix sophorae flavescentis. An ethanol aqueous solution with the concentration of 50% is used for carrying out heating reflux on the crude medicines in the first set; the extracting solution is concentrated into an extract; and pharmaceutical adjuvants are added into the extract to prepare a traditional Chinese medicine granule preparation. The crude medicines in the second set are decocted by using water, and the decoction is taken twice a day respectively in the morning and in the evening. According to the traditional Chinese medicine composition disclosed by the invention, the natural traditional Chinese medicines are used as the raw materials, the comprehensive action of various traditional Chinese medicines is taken for treating the chronic type hepatitis B, the efficacies achieve synergistic effect when all the medicines are used in combination, and the purposes of resolving the current problems and eliminating the root causes are reached.

The invention relates to a Chinese patent medicine (Wuwei Zhuanbian powder) for treating chronic viral hepatitis B and a preparation method thereof, which relates to a traditional Chinese medicine for treating chronic viral hepatitis B in the department of infectious diseases with positive HBV DNA and elevated ALT. By. A Chinese patent medicine for turning HBVDNA negative, HBeAg seroconversion or negative turning in the three yang, and ALT normalization, and a preparation method thereof. The medicine prepared by the present invention is prepared from the following Chinese medicinal materials in proportion by weight: Polyporus 9-15; Banlangen 10-30; Lentinus edodes 10-30; Salvia miltiorrhiza 10-20; Its production method is that the medicinal materials are quantitatively weighed, some of the medicinal materials are extracted with ethanol at a specified concentration and at a prescribed time; After drying in vacuum at high temperature, it is crushed and sieved into powder or subdivided into capsules to form capsules, flooded into pills, packaged and labeled.

The invention relates to a Chinese medicinal formula for treating chronic virus B hepatitis, which is a worldwide disease caused by hepatitis B virus. According to statistics, the number of asymptomatic HBV (hepatitis B virus) carrier exceeds 280 million all over the world, and China accounts for 45%. Most of the patients are asymptomatic, and 1 / 3 of the patients show liver damage clinically. Currently, the number of hepatitis B patients in China totals 30 million. Hepatitis B is characterized by slow onset, and common subclinical and chronic types. And patients with persistent positive non-icteric HBsAg (hepatitis B surface antigen) are likely to become chronic. The disease of chronic virus B hepatitis is mainly transmitted by means of blood, mother-baby, and sexual contact. Virus B hepatitis vaccines in the traditional sense can prevent and treat a lot of hepatitis viruses effectively, but due to individual differences, many patients still show maladjustment.

The invention discloses radix bupleuri and baical skullcap root detoxification granules which are compounded by radix bupleuri, baical skullcap root, white paeony root, herba lycopi, Chinese angelica, salvia miltiorrhiza, Indian buead, bighead atractylodes rhizome, turtle shell, tortoise plastron, oldenlandia diffusa, sculellaria barbata, rhizoma cyperi, Jiaozha, malt, medicated leaven, honey-fried licorice root and Chinese date. The materials are crushed into granules by employing a bluestone tool and are allowed to pass through a 6# (150mu m+ / -6.6mu m) nylon sieve with the particle size of 100 meshes, and the prepared granules are filled in an aluminum foil bag for later use. The radix bupleuri and baical skullcap root detoxification granules have the beneficial effects that the granules have the good effects of resisting hepatitis B virus, improving the symptoms, improving the liver function, regulating the immunologic function and preventing hepatic fibrosis and cirrhosis in the treatment of chronic viral hepatitis B, and the total effective rate is 93.3 percent.

The invention discloses a humanized single chain antibody of anti-hepatitis B virus surface antigen a determinant, the amino acid sequence thereof is SEQ ID NO: 1. The VH amino acid sequence of the antibody is SEQ ID NO: 2, and the VL amino acid sequence of the antibody is SEQ ID NO: 3. The humanized single chain antibody of the anti-hepatitis B virus surface antigen a determinant is used for preparing preventive passive immunity drug or preparing medicines for treating chronic viral hepatitis B.

The invention aims to solve the problem that a non-invasive diagnosis method is hardly available for confirming the hepatic pathological state of people with alanine transaminase (ALT) being less than two times of an upper normal limit in the prior art, and provides a system for predicting a liver inflammatory degree of a chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. The system comprises a detection module, an Inf-index1 calculation module and a liver inflammatory degree prediction module, wherein the detection module is used for detecting hepatitis B core antibody content, glutamic oxalacetic transaminase content and albumin content in serum of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit; the Inf-index1 calculation module is used for calculating Inf-index1 according to the hepatitis B core antibody content, the glutamic oxalacetic transaminase content and the albumin content; the liver inflammatory degree prediction module is used for predicting the liver inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. As proved by clinical test, the system has high prediction accuracy on the inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than the double upper normal limit, and a novel method is provided for clinical diagnosis.

The invention discloses a long-lived plasma cell that secretes PD-1 antibody, and a preparation method and application thereof. Specifically, the PD-1 antibody gene is site-specifically integrated into B cells to obtain genetically engineered B cells; the genetically engineered B cells are induced to become long-lived plasma cells that secrete PD-1 antibody. The long-lived plasma cells secreting PD-1 antibody prepared by the present invention not only have the typical phenotype and transcription characteristics of long-lived plasma cells, but also can continuously secrete a large amount of PD-1 antibody, which is expected to replace the tumor mediated by PD-1 antibody drugs Immunotherapy, and the present invention provides a new idea for adoptive cell immunotherapy of tumors. In addition, the present invention introduces antibody genes into B cells and induces long-lived plasma cells that can continuously secrete large amounts of antibodies, and the new idea therapy of returning the long-lived plasma cells to patients for treatment can not only be used for the treatment of various tumors, but also in various infections. It also has broad application prospects in sexually transmitted diseases such as AIDS and chronic viral hepatitis B, as well as in protein-deficiency diseases such as hemophilia.

The invention discloses a traditional Chinese medicine composition for treating chronic virus b hepatitis through immunity regulation and control, which is prepared from the following raw medicinal materials in parts by weight: 20-10 parts of glossy privet fruit, 20-10 parts of herba epimedii, 20-10 parts of ternate buttercup root, 20-10 parts of root-bark of tree peony, 10-5 parts of picrorhiza rhizome and 10-5 parts of green tangerine orange peel. Shown by clinical practice, the traditional Chinese medicine composition of the invention has immunoregulation effect similar to that of interferon, and has a certain correction effect on the immunity tolerance induced by hepatitis b virus infection.

The invention discloses a Chinese medicinal injection for treating jaundice and a preparation method thereof, which belong to the technical field of Chinese medicinal preparations. The preparation method of the Chinese medicinal injection comprises the following steps of: performing water cooking and alcohol deposition on virgate wormwood herb, fructus gardenia, baikal skullcap root and coptis root to obtain an acid alcohol liquid, performing ethanol percolation on amur corktree bark and rhubarb to obtain an ethanol percolate, mixing the acid alcohol liquid with the ethanol percolate, performing alcohol deposition, adding a concentrated ammonium solution for adjusting the pH value to 8.0-9.0, extracting a supernatant to obtain an alkaline alcohol liquid, concentrating under reduced pressure, and recovering ethanol to obtain a liquid medicament; and adding a proper amount of water for injection into the liquid medicament, filtering and sterilizing to obtain a Chinese medicinal injection for treating jaundice, wherein every 1mL of Chinese medicine injection contains more than or equal to 1.0mg of geniposide C17H24011. The Chinese medicinal injection provided by the invention has the advantage of good treatment effect on jaundice of chronic virus B hepatitis.

The invention belongs to the technical field of biology, and relates to a microRNA (miRNA) used for predicting curative effect of interferon on chronic HBV and application thereof. The serum miRNA combination is mainly composed of two kinds of mature miRNA such as human cytomegalovirus-derived hcmv-mir-US4 and hcmv-mir-UL148D. The screened-out HCMV miRNA combination has the specificity and the sensitivity of predicting the curative effect of using interferon to treat chronic viral hepatitis B patients, and the specificity and the sensitivity are substantially higher than those of current clinic experience prediction, and thus the prediction accuracy is improved.